---
title: "Oramed Pharmaceuticals Inc. (ORMP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ORMP.US.md"
symbol: "ORMP.US"
name: "Oramed Pharmaceuticals Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T05:02:16.614Z"
locales:
  - [en](https://longbridge.com/en/quote/ORMP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ORMP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ORMP.US.md)
---

# Oramed Pharmaceuticals Inc. (ORMP.US)

## Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [oramed.com](https://oramed.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.47)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 87 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 431.80% |  |
| P/B Ratio | 0.88 |  |
| Dividend Ratio | 5.77% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 175131955.07 |  |
| Revenue | 2000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 36.56% | A |
| Profit Margin | 3202.50% | A |
| Gross Margin | 0.65% | E |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | 431.80% | A |
| Total Assets YoY | 48.68% | A |
| Net Assets YoY | 37.43% | A |
| Cash Flow Margin | -14.46% | D |
| OCF YoY | 0.00% | D |
| Turnover | 0.01 | E |
| Gearing Ratio | 13.48% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Oramed Pharmaceuticals Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "431.80%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.88",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "5.77%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "175131955.07",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "36.56%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "3202.50%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "0.65%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "431.80%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "48.68%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "37.43%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-14.46%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.48%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 2.77 | 3/190 | 3.10 | 2.79 | 2.46 |
| PB | 0.88 | 43/190 | 0.68 | 0.63 | 0.59 |
| PS (TTM) | 87.57 | 149/190 | 68.46 | 51.54 | 44.32 |
| Dividend Yield | 5.77% | 4/190 | 7.49% | 7.18% | 6.44% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-26T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.33 |
| Highest Target | 6.25 |
| Lowest Target | 6.25 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ORMP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ORMP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ORMP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ORMP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**